NEW YORK – T2 Biosystems announced Wednesday it has regained compliance with the Nasdaq's minimum bid price continued listing requirement.
In April, the company was notified it wasn't in compliance with the requirement because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days.
The Lexington, Massachusetts-based firm regained compliance by maintaining a minimum closing bid price of at least $1.00 for 10 consecutive trading days, which it did on June 15.
At the close of the market Tuesday, T2 Bio shares were down nearly 6 percent at $1.54.